A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study (bulleted)
Carol Moreno, MD, Marco Montillo, MD, Panayiotidis Panayiotis, MD, et al.
Key Points:
In this abstract, the authors reported the safety profile of Ofatumumab outside clinical trials from CLL patients that were previously treated.
Efficacy, progression-free survival and overall survival were reported.
Patient included had bulky lymphadenopathy and had advanced clinical stage.
Cytogenetics are also analyzed.
Most of the toxicities were hematologic and depends on the number of previous therapies.
Non-hematologic toxicities are also observed
Implications:
The results are consistent with that observed in clinical trials.
Overall response rate is lower in this study
The PFS and OS are the same as in phase II trials.
View the original abstract on the ASH website.
